---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-242398"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T11:26:39.924876+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD CEO departs; co-founder & CBO named interim co-CEOs; strategic review ongoing

## Summary
- CEO Hugh O'Dowd departed Sept 6, 2022; termination without 'Good Cause' triggers severance.
- Dr. Brian Bernick (co-founder, Chief Scientific/Medical Officer) and Mark Glickman (Chief Business Officer) named Interim Co-CEOs.
- Tommy Thompson, former Chairman since 2012, appointed Executive Chairman.
- Press release states the Company continues its robust strategic alternatives process.

## SEC filing metadata
- accession: 0001193125-22-242398
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/d395778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-242398
- JSON: https://secwatch.observer/filing/0001193125-22-242398.json
- Plain text: https://secwatch.observer/filing/0001193125-22-242398.txt

## Key facts
- Executive change
  Tommy Thompson was appointed as Executive Chairman at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: the Board appointed The Honorable Tommy Thompson, who previously served as the Company’s Chairman of the Board, as the Executive Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm
- Executive change
  Mark Glickman was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Interim Co-Chief Executive Officer
  source text: On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm
- Executive change
  Hugh O'Dowd departed as Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: termination without 'Good Cause'
  - Role: Chief Executive Officer
  source text: Mr. O’Dowd’s separation as the Company’s Chief Executive Officer is a termination without “Good Cause,”
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm
- Executive change
  Brian Bernick was appointed as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Interim Co-Chief Executive Officer
  source text: On September 6, 2022, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Dr. Brian Bernick, the Company’s co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company’s Chief Business Officer, as the Company’s Interim Co-Chief Executive Officers
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.